

## The New Era of Uveitis: Embracing Modern Technology

### Course organizers

*Chairperson:* Vishali Gupta, MD

*Course Coordinators:* Rupesh Vijay Agrawal, MD, FRCS, MMed, Esen K. Akpek, MD, David S. Chu, MD, Phoebe Lin, MD, PhD, Careen Y. Lowder, MD, PhD, Quan Dong Nguyen, MD MSc, FARVO and Carlos E. Pavesio, FRCOphth, MD

### Cutting edge treatments for uveitis

*Moderators:* Quan Dong Nguyen, MD MSc, FARVO and John H. Kempen, MD, MPH, MHS, PhD  
 1:05 – 3:05pm

This session will highlight the advances in the field of treatment of uveitis. The experts shall cover a wide array of spectrum beginning with conventional treatment and elaborating on round the corner newer therapies including both local and systemic therapies.

<b>Presentations</b>		
<b>1:05 PM</b>	Standard of care (or consensus care) treatment	John H. Kempen, MD, MPH, MHS, PhD
<b>1:20 PM</b>	Clinical trials: What Are Practical and Relevant Endpoints?	Sunil K Srivastava, MD
<b>1:35 PM</b>	Novel Systemic therapeutic targets	Quan Dong Nguyen, MD MSc, FARVO
<b>1:50 PM</b>	Novel Local therapeutic targets	Bahram Bodaghi, MD, PhD
<b>Case study</b>		
<b>2:05 PM</b>	Case illustrating treatment dilemma	Igor Kozak, MD, PhD
<b>Debates: Local vs. systemic therapy</b>		
<i>Local therapy: Saves patients from Systemic side effects</i>		
<b>2:15 PM</b>	Debate 1: Local therapy saves patients from systemic side effects.	Jia-Horung Hung, MD

<b>2:25 PM</b>	Debate 1: Local therapy does not save patient from systemic side effects.	Sunil K Srivastava, MD
<b>2:35 PM</b>	Debate 1: Voting & Concluding Remarks	Quan Dong Nguyen, MD MSc, FARVO
<i>Systemic therapy with Biologics: First Line or Last Resort?</i>		
<b>2:40 PM</b>	Debate 2: Systemic therapy with biologics should be used as a first line treatment option.	Christopher Or
<b>2:50 PM</b>	Debate 2: Systemic therapy with biologics should be used as a last resort treatment option.	Mudit Tyagi, MD
<b>3:00 PM</b>	Voting & Concluding Remarks	Bahram Bodaghi, MD, PhD